colorectal liver metastases
Conditions
Interventions
D-TACE group:D-TACE+Regorafenib
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients with colorectal liver metastases,and have clear pathology; 2.No obstructive jaundice; No large vessel invasion; Meet the indications for interventional chemoembolization; 3.Voluntary taking anti-angiogenic drugs as a third-line treatment, Willing to accept interventional treatment; 4.The patient voluntarily participated in the study and signed an informed consent form; 5.18-80 years old; no gender limit; 6.Evaluable lesions according to RECIST standards.
Exclusion criteria
Exclusion criteria: 1.Patients who cannot be followed up as required by the study; 2.Patients without independent decision-making ability or mental illness; 3.Patients who are using other chemotherapy drugs and targeted drugs; 4.Patients with severe heart, brain, liver, and kidney system diseases; 5.The expected survival time is less than 3 months; 6.Those who are allergic or intolerant to the use of anti-angiogenic drugs and drug-eluting microspheres; 7.Those who are contraindicated in the use of anti-angiogenic drugs and drug-eluting microspheres.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time-to-Disease Progression;Objective Response Rate; | — |
Countries
China
Contacts
Public ContactZhou Bo
Zhongshan Hospital, Fudan University
Outcome results
None listed